Literature DB >> 18191405

Transcriptional dysregulation in a transgenic model of Parkinson disease.

Talene A Yacoubian1, Ippolita Cantuti-Castelvetri, Bérengère Bouzou, Georgios Asteris, Pamela J McLean, Bradley T Hyman, David G Standaert.   

Abstract

Alpha-synuclein has been implicated in Parkinson disease, yet the mechanism by which alpha-synuclein causes cell injury is not understood. Using a transgenic mouse model, we evaluated the effect of alpha-synuclein overexpression on gene expression in the substantia nigra. Nigral mRNA from wild type and alpha-synuclein transgenic mice was analyzed using Affymetrix gene arrays. At 3 months, before pathological changes are apparent, we observed modest alterations in gene expression. However, nearly 200 genes were altered in expression at 9 months, when degenerative changes are more apparent. Functional genomic analysis revealed that the genes altered at 9 months were predominantly involved in gene transcription. As in human Parkinson disease, gene expression changes in the transgenic model were also modulated by gender. These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18191405      PMCID: PMC2707844          DOI: 10.1016/j.nbd.2007.11.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  60 in total

1.  Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein.

Authors:  A Athanassiadou; G Voutsinas; L Psiouri; E Leroy; M H Polymeropoulos; A Ilias; G M Maniatis; T Papapetropoulos
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

4.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

5.  alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease.

Authors:  C K Wang; C M Chen; C Y Chang; K H Chang; I C Chen; M L Li; G-J Lee-Chen; Y R Wu
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

6.  Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats.

Authors:  Andrea Tamás; Andrea Lubics; Luca Szalontay; István Lengvári; Dóra Reglodi
Journal:  Behav Brain Res       Date:  2005-03-30       Impact factor: 3.332

7.  Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.

Authors:  Oliver von Bohlen und Halbach; Liliana Minichiello; Klaus Unsicker
Journal:  FASEB J       Date:  2005-07-21       Impact factor: 5.191

8.  Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.

Authors:  R Krüger; A M Vieira-Saecker; W Kuhn; D Berg; T Müller; N Kühnl; G A Fuchs; A Storch; M Hungs; D Woitalla; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Ann Neurol       Date:  1999-05       Impact factor: 10.422

9.  Effects of gender on nigral gene expression and parkinson disease.

Authors:  Ippolita Cantuti-Castelvetri; Christine Keller-McGandy; Bérengère Bouzou; Georgios Asteris; Timothy W Clark; Matthew P Frosch; David G Standaert
Journal:  Neurobiol Dis       Date:  2007-03-03       Impact factor: 5.996

10.  Considerations when using the significance analysis of microarrays (SAM) algorithm.

Authors:  Ola Larsson; Claes Wahlestedt; James A Timmons
Journal:  BMC Bioinformatics       Date:  2005-05-29       Impact factor: 3.169

View more
  35 in total

Review 1.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

4.  A neuroprotective role for angiogenin in models of Parkinson's disease.

Authors:  Trent U Steidinger; David G Standaert; Talene A Yacoubian
Journal:  J Neurochem       Date:  2010-12-22       Impact factor: 5.372

5.  Continuously tunable Ca(2+) regulation of RNA-edited CaV1.3 channels.

Authors:  Hojjat Bazzazi; Manu Ben Johny; Paul J Adams; Tuck Wah Soong; David T Yue
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

6.  Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Authors:  Franziska Richter; Fuying Gao; Vera Medvedeva; Patrick Lee; Nicholas Bove; Sheila M Fleming; Magali Michaud; Vincent Lemesre; Stefano Patassini; Krystal De La Rosa; Caitlin K Mulligan; Pedrom C Sioshansi; Chunni Zhu; Giovanni Coppola; Thierry Bordet; Rebecca M Pruss; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2014-05-18       Impact factor: 5.996

7.  14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.

Authors:  Bing Wang; Rachel Underwood; Anjali Kamath; Colleen Britain; Michael B McFerrin; Pamela J McLean; Laura A Volpicelli-Daley; Robert H Whitaker; William J Placzek; Katelyn Becker; Jiyan Ma; Talene A Yacoubian
Journal:  J Neurosci       Date:  2018-08-09       Impact factor: 6.167

Review 8.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

9.  Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease.

Authors:  You Me Sung; Taehee Lee; Hyejin Yoon; Amanda Marie DiBattista; Jung Min Song; Yoojin Sohn; Emily Isabella Moffat; R Scott Turner; Mira Jung; Jungsu Kim; Hyang-Sook Hoe
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

10.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.